- Home
- / Sosei Heptares
Sosei Heptares
Stock Price
$7.1
2024-10-29
Market Capitalization
$697 M
2024-10-29
Revenue
¥29.6 B
FY, 2025
Sosei Heptares Summary
Company Summary
- Overview
- Sosei Heptares is a biopharmaceutical company that specializes in drug development. It offers medicines in therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases.
- Type
- Public
- Status
- Active
- Founded
- 1990
- HQ
- Tokyo, JP | view all locations
- Website
- https://soseiheptares.com
- Cybersecurity rating
Table of Contents
Key People
Shinichi Tamura, Chairman of the Board
Malcolm Weir, Executive Vice Chairman
David Roblin, External Independent Director
Operating MetricsView all
Locations
3
Jun, 2023
LocationsView all
4 locations detected
Tokyo, 東京都 HQ
Japan
PMO Hanzomon 11F, 2-1 Kojimachi, Chiyoda-ku
Dublin, D
Ireland
88 Harcourt Street
Cambridge, England
United Kingdom
Steinmetz Building, Granta Park
London, England
United Kingdom
North West House, 119 Marylebone Road
Sosei Heptares Financials
Summary Financials
- Revenue (FY, 2025)
- ¥29.6B
- Gross profit (FY, 2025)
- ¥24.0B
- Net income (FY, 2025)
- (¥12.5B)
- Cash (FY, 2025)
- ¥20.4B
- EBIT (FY, 2025)
- (¥8.5B)
- Enterprise value
- $37.7B